

Resource Summary Report

Generated by [dkNET](#) on Sep 18, 2026

Brilliant Violet 421(TM) anti-human CD45

RRID:AB_2561357

Type: Antibody

Proper Citation

BioLegend Cat# 304032, RRID:AB_2561357

Antibody Information

URL: http://antibodyregistry.org/AB_2561357

Proper Citation: BioLegend Cat# 304032, RRID:AB_2561357

Target Antigen: CD45

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 421(TM) anti-human CD45

Description: This monoclonal targets CD45

Target Organism: human

Clone ID: Clone HI30

Antibody ID: AB_2561357

Vendor: BioLegend

Catalog Number: 304032

Alternative Catalog Numbers: 304031

Record Creation Time: 20231110T035231+0000

Record Last Update: 20260829T230555+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 421(TM) anti-human CD45.

No alerts have been found for Brilliant Violet 421(TM) anti-human CD45.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 27 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Iba T, et al. (2026) CD157+ vascular endothelial stem cells represent a conserved subpopulation with an angiogenic gene expression profile. Stem cell reports, 21(7), 102931.

Waclawiczek A, et al. (2026) Leukemic stem cell subtypes determine venetoclax resistance and therapeutic vulnerabilities in AML. Cell stem cell, 33(6), 982.

Sobu R, et al. (2026) IL-8 blockade enhances anti-PD-1 therapeutic activity in renal cell carcinoma in a next-generation patient-derived xenograft model. iScience, 29(7), 116386.

Guo X, et al. (2025) Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer. Cancer cell, 43(2), 248.

Aznar MA, et al. (2025) Clinical and molecular dissection of CAR T cell resistance in pancreatic cancer. Cell reports. Medicine, 6(9), 102301.

Zhang Y, et al. (2025) Cancer cells co-opt an inter-organ neuroimmune circuit to escape immune surveillance. Cell, 188(24), 6754.

Seo S, et al. (2025) Allelic bias contributes to heterogeneous phenotypes of NK cell deficiency. Cell reports, 44(8), 116102.

Ni Y, et al. (2024) Human yolk sac-derived innate lymphoid-biased multipotent progenitors emerge prior to hematopoietic stem cell formation. Developmental cell, 59(19), 2626.

Liu C, et al. (2024) Protocol for in vitro generation of innate lymphoid cells from human embryonic tissues. STAR protocols, 6(1), 103525.

Zhang Y, et al. (2024) Generation of dual-attribute iTNK cells from hPSCs for cancer immunotherapy. Cell reports methods, 4(9), 100843.

Loh L, et al. (2024) Unraveling the phenotypic states of human innate-like T cells: Comparative insights with conventional T cells and mouse models. Cell reports, 43(9), 114705.

Liu H, et al. (2024) Lipid imbalance and inflammatory oxylipin cascade at the maternal-fetal interface in recurrent spontaneous abortion. *Heliyon*, 10(24), e40515.

Agarwal S, et al. (2023) Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells. *Immunity*, 56(10), 2388.

Jia Q, et al. (2023) Comparing HD knockin pigs and mice reveals the pathological role of IL-17. *Cell reports*, 42(12), 113443.

Synn CB, et al. (2022) SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer models. *Clinical & translational immunology*, 11(1), e1364.

Kersten K, et al. (2022) Spatiotemporal co-dependency between macrophages and exhausted CD8⁺ T cells in cancer. *Cancer cell*, 40(6), 624.

Liu X, et al. (2021) Distinct human Langerhans cell subsets orchestrate reciprocal functions and require different developmental regulation. *Immunity*, 54(10), 2305.

Park JA, et al. (2021) Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response. *Journal of hematology & oncology*, 14(1), 142.

Maat H, et al. (2021) The USP7-TRIM27 axis mediates non-canonical PRC1.1 function and is a druggable target in leukemia. *iScience*, 24(5), 102435.

Good CR, et al. (2021) An NK-like CAR T cell transition in CAR T cell dysfunction. *Cell*, 184(25), 6081.